Climb Bio (CLYM) Cash from Operations (2020 - 2026)
Climb Bio (CLYM) reported Cash from Operations of 14379000.0 for Q1 2026, up 6.84% on a YoY basis from 13459002.12 in Q1 2025, and up 8.03% quarter-over-quarter from 15635000.0 in Q4 2025.
Climb Bio (CLYM) Cash from Operations (2020 - 2026) Analysis & Trends
Climb Bio has reported Cash from Operations for 7 years, with the latest figure at 14379000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 6.84% year-over-year to 14379000.0; the trailing twelve-month figure through Mar 2026 stood at 53301000.0 (down 82.68% YoY), and the FY2025 full-year result was 54356000.0, down 249.29% from the prior year.
- Cash from Operations for Q1 2026 stood at 14379000.0, up from 15635000.0 in the prior quarter.
- The five-year high for Cash from Operations was 3490000.0 in Q3 2023, with the low at 15635000.0 in Q4 2025.
- Historically, Cash from Operations has averaged 8368529.41 across 5 years, with a median of 8449000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 183.59% — and 2025, when it tumbled 1571.36%.
- Climb Bio's Cash from Operations stood at 8449000.0 in 2022, then jumped by 88.79% to 947000.0 in 2023, then sank by 483.0% to 5521000.0 in 2024, then tumbled by 183.19% to 15635000.0 in 2025, then increased by 8.03% to 14379000.0 in 2026.
- The last three Cash from Operations figures came in at 14379000.0 (Q1 2026), 15635000.0 (Q4 2025), and 12139000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Climb Bio | 740.73 Mn | 740.73 Mn | - | -14.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.38 Mn |
| Mar 31, 2026 | -14.38 Mn |
| Dec 31, 2025 | -15.64 Mn |
| Dec 31, 2025 | -15.64 Mn |
| Sep 30, 2025 | -12.14 Mn |
| Sep 30, 2025 | -12.14 Mn |
| Jun 30, 2025 | -11.15 Mn |
| Jun 30, 2025 | -11.15 Mn |
| Mar 31, 2025 | -15.43 Mn |
| Mar 31, 2025 | -15.43 Mn |
| Dec 31, 2024 | -5.52 Mn |
| Dec 31, 2024 | -5.52 Mn |
| Sep 30, 2024 | -7.56 Mn |
| Sep 30, 2024 | -7.56 Mn |
| Jun 30, 2024 | -667,000.00 |
| Jun 30, 2024 | -667,000.00 |
| Mar 31, 2024 | -1.82 Mn |
| Mar 31, 2024 | -1.82 Mn |
| Dec 31, 2023 | -947,000.00 |
| Dec 31, 2023 | -947,000.00 |